艾迪联合紫杉醇+顺铂化疗方案治疗晚期非小细胞肺癌的临床观察(1)
【摘要】 目的：观察艾迪联合紫杉醇+顺铂(TP)方案治疗晚期非小细胞肺癌的临床效果。
方法：选取2015年1月-2017年6月本院收治的确诊为非小细胞肺癌晚期患者68例，按照随机数字表法将所有患者分为对照组和观察组，各34例。对照组患者给予TP方案进行治疗，观察组在对照组的基础上给予艾迪注射液。观察治疗4个周期后，两组患者的近期疗效、生活质量Karnofshy评分及毒副反应发生情况。结果：观察组近期临床总有效率为67.65%，虽高于对照组的52.94%，但差异无统计学意义(P>0.05)；观察组的近期临床收益率为88.24%，明顯高于对照组的58.82%，差异有统计学意义( 字2=7.556，P=0.006)。观察组患者治疗后生活质量Karnofsky评分提高率为64.71%，明显高于对照组的38.24%( 字2=4.77，P<0.05)。两组患者主要毒副反应为骨髓抑制和胃肠道反应，观察组患者白细胞减少和血小板减少的发生率均明显低于对照组，差异有统计学意义( 字2=8.35、4.87，P<0.05)。结论：艾迪联合TP化疗方案治疗晚期非小细胞肺癌可有效提高临床收益率，比单独使用TP方案化疗毒副反应小，可显著改善患者生活质量。
, 百拇医药
【关键词】 艾迪注射液； 紫杉醇； 顺铂； 非小细胞肺癌
Clinical Observation of Aidi Injection Combined with Paclitaxel and Cisplatin Regimen in the Treatment of Advanced Non-small Cell Lung Cancer/LIN Xiaowei.//Medical Innovation of China，2018，15(03)：062-065
【Abstract】 Objective：To observe the clinical efficacy of Aidi Injection combined with Paclitaxel+Cisplatin(TP)in the treatment of advanced non-small cell lung cancer.Method：From January 2015 to June 2017，68 patients with advanced non-small cell lung cancer (NSCLC) were selected and divided into control group and observation group，34 cases in each group.The patients in the control group were treated with TP regimen，the observation group was given Aidi Injection on the basis of the control group.The short-term efficacy，quality of life Karnofshy score and side effects were compared between the two groups after 4 cycles of treatment.Result：The total clinical effective rate in the observation group was 67.65%，higher than 52.94% in the control group，but the difference was not statistically significant(P>0.05).The recent clinical yields of the observation group was 88.24%，which was significantly higher than 58.82% the control group( 字2=7.556，P=0.006).After treatment，the quality of life Karnofsky score increase rate in the observation group was 64.71%，significantly higher than 38.24% of the control group( 字2=4.77，P<0.05).The main side effects of the two groups were bone marrow depression and gastrointestinal reaction，the incidence of leukocyte reduction and thrombocytopenia in the observation group were significantly lower than those in the control group ( 字2=8.35，4.87，P<0.05).Conclusion：Aidi Injection combined with TP regimen in the treatment of advanced non-small cell lung cancer can effectively improve the clinical benefit，which is better than that of GP regimen alone，which can improve the quality of life of patients.
【Key words】 Aidi Injection； Paclitaxel； Cisplatin； Non-small cell lung cancer, 百拇医药(林晓伟)
方法：选取2015年1月-2017年6月本院收治的确诊为非小细胞肺癌晚期患者68例，按照随机数字表法将所有患者分为对照组和观察组，各34例。对照组患者给予TP方案进行治疗，观察组在对照组的基础上给予艾迪注射液。观察治疗4个周期后，两组患者的近期疗效、生活质量Karnofshy评分及毒副反应发生情况。结果：观察组近期临床总有效率为67.65%，虽高于对照组的52.94%，但差异无统计学意义(P>0.05)；观察组的近期临床收益率为88.24%，明顯高于对照组的58.82%，差异有统计学意义( 字2=7.556，P=0.006)。观察组患者治疗后生活质量Karnofsky评分提高率为64.71%，明显高于对照组的38.24%( 字2=4.77，P<0.05)。两组患者主要毒副反应为骨髓抑制和胃肠道反应，观察组患者白细胞减少和血小板减少的发生率均明显低于对照组，差异有统计学意义( 字2=8.35、4.87，P<0.05)。结论：艾迪联合TP化疗方案治疗晚期非小细胞肺癌可有效提高临床收益率，比单独使用TP方案化疗毒副反应小，可显著改善患者生活质量。
, 百拇医药
【关键词】 艾迪注射液； 紫杉醇； 顺铂； 非小细胞肺癌
Clinical Observation of Aidi Injection Combined with Paclitaxel and Cisplatin Regimen in the Treatment of Advanced Non-small Cell Lung Cancer/LIN Xiaowei.//Medical Innovation of China，2018，15(03)：062-065
【Abstract】 Objective：To observe the clinical efficacy of Aidi Injection combined with Paclitaxel+Cisplatin(TP)in the treatment of advanced non-small cell lung cancer.Method：From January 2015 to June 2017，68 patients with advanced non-small cell lung cancer (NSCLC) were selected and divided into control group and observation group，34 cases in each group.The patients in the control group were treated with TP regimen，the observation group was given Aidi Injection on the basis of the control group.The short-term efficacy，quality of life Karnofshy score and side effects were compared between the two groups after 4 cycles of treatment.Result：The total clinical effective rate in the observation group was 67.65%，higher than 52.94% in the control group，but the difference was not statistically significant(P>0.05).The recent clinical yields of the observation group was 88.24%，which was significantly higher than 58.82% the control group( 字2=7.556，P=0.006).After treatment，the quality of life Karnofsky score increase rate in the observation group was 64.71%，significantly higher than 38.24% of the control group( 字2=4.77，P<0.05).The main side effects of the two groups were bone marrow depression and gastrointestinal reaction，the incidence of leukocyte reduction and thrombocytopenia in the observation group were significantly lower than those in the control group ( 字2=8.35，4.87，P<0.05).Conclusion：Aidi Injection combined with TP regimen in the treatment of advanced non-small cell lung cancer can effectively improve the clinical benefit，which is better than that of GP regimen alone，which can improve the quality of life of patients.
【Key words】 Aidi Injection； Paclitaxel； Cisplatin； Non-small cell lung cancer, 百拇医药(林晓伟)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺肿瘤 > 肺癌